Assessment of ctDNA in CSF may be a more rapid means of assessing surgical outcomes than plasma ctDNA in glioblastoma

Publication date: Available online 4 June 2019Source: Molecular and Cellular ProbesAuthor(s): Jue-hui Li, Zhen-qiang He, Fu-hua Lin, Zheng-he Chen, Shi-yu Yang, Hao Duan, Xiao-bing Jiang, Fuad Al-Nahari, Xiang-heng Zhang, Jiang-huang Wang, Guan-hua Zhang, Zhen-feng Zhang, Cong Li, Yong-Gao MouAbstractWe aimed to develop a high-throughput deep DNA sequencing assay of cerebrospinal fluid (CSF) to identify clinically relevant oncogenic mutations that contribute to the development of glioblastoma (GBM) and serve as biomarkers to predict patients' responses to surgery. For this purpose, we recruited five patients diagnosed with highly suspicious GBM according to preoperative magnet resonance imaging. Subsequently, patients were histologically diagnosed with GBM. CSF was obtained through routine lumbar puncture, and plasma from peripheral blood was collected before surgery and 7 days after. Fresh tumor samples were collected using routine surgical procedures. Targeted deep sequencing was used to characterize the genomic landscape and identify mutational profile that differed between pre-surgical and post-surgical samples. Sequence analysis was designed to detect protein-coding exons, exon-intron boundaries, and the untranslated regions of 50 genes associated with cancers of the central nervous system. Circulating tumor DNAs (ctDNAs) were prepared from the CSF and plasma from peripheral blood. For comparison, DNA was isolated from fresh tumor tissues. Non-silent coding variants were...
Source: Molecular and Cellular Probes - Category: Molecular Biology Source Type: research